fate therapeutics stock price target

Fate Therapeutics upgraded to outperform from neutral at Wedbush price target raised to 74 from 71 MarketWatch. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.

Block Sq Stock Forecast Is It Time To Buy The Dip

Sign in to your SmartPortfolio to see more analyst recommendations.

. According to analysts consensus price target of 9300 Fate Therapeutics has a forecasted upside of 1686 from its current price of 3463. Stock information by Barrons. FATE stock price quote with breaking news financials statistics charts and more.

Amount of Analyst Coverage. Fate Therapeutics NASDAQFATE Get Rating had its price target reduced by analysts at Truist Financial from 12500 to 7500 in a research note issued to investors on Wednesday The Fly reports. Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Ratin.

The latest price target for Fate Therapeutics NASDAQ. Fate Therapeutics Inc FATE stock is trading at 3859 as of 940 AM on Friday Feb 11 an increase of 047 or 125 from the previous closing price of 3811. Fate Therapeutics Inc.

Average price target from 19 ratings. Get a real-time Fate Therapeutics Inc. 69 rows FATE Stock Trend.

7 2020 at 718 am. Ad Our Strong Buys Double the SP. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist.

Based On Fundamental Analysis. Find the latest Fate Therapeutics Inc. 5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400.

AFTER HOURS 543 PM EDT 041222. Morgan Stanley Adjusts Fate Therapeutics Price Target to 52 From 62 Maintains Equalweig. Chart FATE THERAPEUTICS INC.

HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rating. In comparison to the median Healthcare stock FATEs pricesales ratio is 11793 higher now standing at 1452. Get a real-time Fate Therapeutics Inc.

The average price target is 000 with a high estimate of 000 and a low estimate of 000. Nasdaq AT CLOSE 400 PM EDT 041222. The stock is moving within a very wide and.

13000 The average price target includes all analyst analysis not just the most recent analysis presented in the chart. Wednesday December 15 2021. The average twelve-month price target for Fate Therapeutics is 9300 with a high price target of 14500 and a low price target of 6000.

FATE stock price quote with breaking news financials statistics charts and more. Over the past 96 months FATEs pricesales ratio has gone. HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rati.

9642 1784 Earnings Date. Over the past 96 months FATEs priceearnings ratio has gone down 256. On March 4 2022.

According to the issued ratings of 10 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 8 buy ratings for FATE. Wedbush lifted their target price on shares of Fate Therapeutics from 7400 to 7700 and gave the stock an outperform rating in a research note on Tuesday March 1st. Wednesday April 13 2022.

FATE was reported by HC Wainwright Co. NASDAQFATE shares rose in value on Thursday April 21 with the stock price down by -568 to the previous days close as strong demand from buyers drove the stock to 3452. In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is higher than 145991 of that group.

Fate Therapeutics has only been the subject of 3 research reports in the past 90 days. Complete Fate Therapeutics Inc. FATE stock quote history news and other vital information to help you with your stock trading and investing.

FATE has a greater upside potential average analyst target price relative to current price than 149379 of stocks in the mid market cap category. The stock has traded between 3832 and 3995 so far today. Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec.

View real-time FATE stock price and news along with industry-best analysis. Thursday August 26 2021. Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Rating.

Price Price Target Lowest. Actively observing the price movement in the last trading the stock closed the session at 3660 falling within a range of 34205 and 3869. Volume today is below average.

The analyst firm set a price target for 11500 expecting FATE to rise to within. Fate Therapeutics stock price target cut to 75 from 125 at Truist MarketWatch. Learn more on FATEs analyst rating history.

Could Fate Therapeutics Be A Millionaire Maker Stock The Motley Fool